Cargando…
Pegylated interferon 2a and ruxolitinib induce a high rate of oral complications among patients with myeloproliferative neoplasms
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176112/ https://www.ncbi.nlm.nih.gov/pubmed/35847694 http://dx.doi.org/10.1002/jha2.15 |
| _version_ | 1784722593435090944 |
|---|---|
| author | Orliaguet, Marie Boisramé, Sylvie Eveillard, Jean‐Richard Pan‐Petesch, Brigitte Couturier, Marie‐Anne Rebière, Vincent Guillerm, Gaelle Le Bousse‐Kerdiles, Marie‐Caroline Misery, Laurent Lippert, Eric Ianotto, Jean‐Christophe |
| author_facet | Orliaguet, Marie Boisramé, Sylvie Eveillard, Jean‐Richard Pan‐Petesch, Brigitte Couturier, Marie‐Anne Rebière, Vincent Guillerm, Gaelle Le Bousse‐Kerdiles, Marie‐Caroline Misery, Laurent Lippert, Eric Ianotto, Jean‐Christophe |
| author_sort | Orliaguet, Marie |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9176112 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-91761122022-07-14 Pegylated interferon 2a and ruxolitinib induce a high rate of oral complications among patients with myeloproliferative neoplasms Orliaguet, Marie Boisramé, Sylvie Eveillard, Jean‐Richard Pan‐Petesch, Brigitte Couturier, Marie‐Anne Rebière, Vincent Guillerm, Gaelle Le Bousse‐Kerdiles, Marie‐Caroline Misery, Laurent Lippert, Eric Ianotto, Jean‐Christophe EJHaem Letters John Wiley and Sons Inc. 2020-06-01 /pmc/articles/PMC9176112/ /pubmed/35847694 http://dx.doi.org/10.1002/jha2.15 Text en © 2020 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Letters Orliaguet, Marie Boisramé, Sylvie Eveillard, Jean‐Richard Pan‐Petesch, Brigitte Couturier, Marie‐Anne Rebière, Vincent Guillerm, Gaelle Le Bousse‐Kerdiles, Marie‐Caroline Misery, Laurent Lippert, Eric Ianotto, Jean‐Christophe Pegylated interferon 2a and ruxolitinib induce a high rate of oral complications among patients with myeloproliferative neoplasms |
| title | Pegylated interferon 2a and ruxolitinib induce a high rate of oral complications among patients with myeloproliferative neoplasms |
| title_full | Pegylated interferon 2a and ruxolitinib induce a high rate of oral complications among patients with myeloproliferative neoplasms |
| title_fullStr | Pegylated interferon 2a and ruxolitinib induce a high rate of oral complications among patients with myeloproliferative neoplasms |
| title_full_unstemmed | Pegylated interferon 2a and ruxolitinib induce a high rate of oral complications among patients with myeloproliferative neoplasms |
| title_short | Pegylated interferon 2a and ruxolitinib induce a high rate of oral complications among patients with myeloproliferative neoplasms |
| title_sort | pegylated interferon 2a and ruxolitinib induce a high rate of oral complications among patients with myeloproliferative neoplasms |
| topic | Letters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176112/ https://www.ncbi.nlm.nih.gov/pubmed/35847694 http://dx.doi.org/10.1002/jha2.15 |
| work_keys_str_mv | AT orliaguetmarie pegylatedinterferon2aandruxolitinibinduceahighrateoforalcomplicationsamongpatientswithmyeloproliferativeneoplasms AT boisramesylvie pegylatedinterferon2aandruxolitinibinduceahighrateoforalcomplicationsamongpatientswithmyeloproliferativeneoplasms AT eveillardjeanrichard pegylatedinterferon2aandruxolitinibinduceahighrateoforalcomplicationsamongpatientswithmyeloproliferativeneoplasms AT panpeteschbrigitte pegylatedinterferon2aandruxolitinibinduceahighrateoforalcomplicationsamongpatientswithmyeloproliferativeneoplasms AT couturiermarieanne pegylatedinterferon2aandruxolitinibinduceahighrateoforalcomplicationsamongpatientswithmyeloproliferativeneoplasms AT rebierevincent pegylatedinterferon2aandruxolitinibinduceahighrateoforalcomplicationsamongpatientswithmyeloproliferativeneoplasms AT guillermgaelle pegylatedinterferon2aandruxolitinibinduceahighrateoforalcomplicationsamongpatientswithmyeloproliferativeneoplasms AT leboussekerdilesmariecaroline pegylatedinterferon2aandruxolitinibinduceahighrateoforalcomplicationsamongpatientswithmyeloproliferativeneoplasms AT miserylaurent pegylatedinterferon2aandruxolitinibinduceahighrateoforalcomplicationsamongpatientswithmyeloproliferativeneoplasms AT lipperteric pegylatedinterferon2aandruxolitinibinduceahighrateoforalcomplicationsamongpatientswithmyeloproliferativeneoplasms AT ianottojeanchristophe pegylatedinterferon2aandruxolitinibinduceahighrateoforalcomplicationsamongpatientswithmyeloproliferativeneoplasms |